Insider Transactions in Q4 2021 at Biocryst Pharmaceuticals Inc (BCRX)
Insider Transaction List (Q4 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 14
2021
|
Jon P Stonehouse President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
123,000
+12.0%
|
-
|
|
Dec 14
2021
|
William P Sheridan Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
35,000
+40.8%
|
-
|
|
Dec 14
2021
|
Anthony Doyle Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
115,000
+35.52%
|
-
|
|
Dec 14
2021
|
Alane P Barnes Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
75,000
+25.26%
|
-
|
|
Dec 14
2021
|
Helen M. Thackray Chief R&D Officer |
BUY
Grant, award, or other acquisition
|
Direct |
44,000
+23.4%
|
-
|
|
Dec 14
2021
|
Yarlagadda S Babu Chief Discovery Officer |
BUY
Grant, award, or other acquisition
|
Direct |
35,000
+12.28%
|
-
|
|
Dec 14
2021
|
Charles K Gayer Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
125,000
+32.34%
|
-
|
|
Dec 14
2021
|
Michael L Jones Exec. Director, Finance - PAO |
BUY
Grant, award, or other acquisition
|
Direct |
5,850
+34.31%
|
-
|
|
Dec 07
2021
|
Yarlagadda S Babu Chief Discovery Officer |
SELL
Open market or private sale
|
Direct |
30,100
-12.28%
|
$361,200
$12.2 P/Share
|
|
Dec 07
2021
|
Yarlagadda S Babu Chief Discovery Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
62,000
+20.19%
|
$248,000
$4.73 P/Share
|
|
Nov 30
2021
|
Robert Alexander Ingram Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,554
+1.93%
|
$18,648
$12.06 P/Share
|
|
Nov 30
2021
|
Theresa Heggie Director |
BUY
Grant, award, or other acquisition
|
Direct |
829
+5.04%
|
$9,948
$12.06 P/Share
|
|
Nov 30
2021
|
Alan G Levin Director |
BUY
Grant, award, or other acquisition
|
Direct |
829
+36.26%
|
$9,948
$12.06 P/Share
|
|
Nov 30
2021
|
Steve Aselage Director |
BUY
Grant, award, or other acquisition
|
Direct |
414
+1.24%
|
$4,968
$12.06 P/Share
|
|
Nov 24
2021
|
Vincent Milano Director |
BUY
Open market or private purchase
|
Direct |
7,500
+30.0%
|
$90,000
$12.19 P/Share
|
|
Nov 23
2021
|
Anthony Doyle Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
35,258
+27.34%
|
$423,096
$12.48 P/Share
|
|
Nov 15
2021
|
George B Abercrombie Director |
SELL
Open market or private sale
|
Direct |
5,000
-100.0%
|
$60,000
$12.27 P/Share
|
|
Nov 15
2021
|
George B Abercrombie Director |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+50.0%
|
$15,000
$3.32 P/Share
|
|
Oct 15
2021
|
Nancy J Hutson Director |
SELL
Open market or private sale
|
Direct |
105,000
-61.74%
|
$1,575,000
$15.4 P/Share
|
|
Oct 15
2021
|
Nancy J Hutson Director |
BUY
Exercise of conversion of derivative security
|
Direct |
105,000
+17.0%
|
$315,000
$3.24 P/Share
|